2011
Prognostic Impact of Staged Versus “One-Time” Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Kornowski R, Mehran R, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW, Investigators H. Prognostic Impact of Staged Versus “One-Time” Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2011, 58: 704-711. PMID: 21816305, DOI: 10.1016/j.jacc.2011.02.071.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionMultivessel primary percutaneous coronary interventionMajor adverse cardiovascular eventsHORIZONS-AMI trialAdverse cardiovascular eventsMultivessel diseaseNonculprit lesionsCardiovascular eventsStent thrombosisPCI strategyPrimary PCIAcute Myocardial Infarction AnalysisProbable stent thrombosisTarget vessel revascularizationElevation myocardial infarctionPercutaneous coronary interventionSubgroup of patientsPrimary PCI proceduresMultivessel percutaneous interventionNonculprit vesselsCardiac mortalityCause mortalityCulprit lesionSTEMI patients
2009
Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial
Nikolsky E, Mehran R, Sadeghi HM, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Stone GW. Prognostic Impact of Blood Transfusion After Primary Angioplasty for Acute Myocardial Infarction Analysis From the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial. JACC Cardiovascular Interventions 2009, 2: 624-632. PMID: 19628185, DOI: 10.1016/j.jcin.2009.05.004.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAge FactorsAgedAnemiaAngioplasty, Balloon, CoronaryAntibodies, MonoclonalErythrocyte TransfusionFemaleHeart DiseasesHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesRadiographyRecurrenceRisk AssessmentRisk FactorsSeverity of Illness IndexSex FactorsStrokeTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCIRBC transfusionCADILLAC trialClinical outcomesComposite major adverse cardiac eventsAcute Myocardial Infarction AnalysisMajor adverse cardiac eventsCoronary artery bypass surgeryRed blood cell transfusionMechanical reperfusion therapyAdverse cardiac eventsArtery bypass surgeryBlood cell transfusionTriple vessel diseasePercutaneous coronary interventionBaseline anemiaMajor bleedingTransfusion propensityCell transfusionIndex hospitalizationMultivariable adjustmentPrimary angioplastyReperfusion therapy